Singapore, Oct. 14 -- ITOCHU Corporation has signed a capital alliance agreement with MOLCURE Inc., which possesses AI-driven drug discovery technologies for antibodies and peptides.In recent years, the diversification of pharmaceuticals and therapeutic approaches, increasingly sophisticated research and development, and rising development costs have created a need to improve efficiency throughout the entire R&D process, from drug discovery through clinical development.

Against this backdrop, expectations are growing for AI-driven drug discovery technologies that support the identification and design of drug candidates in the early stages of drug discovery research.MOLCURE has an AI-driven drug discovery platform that combines various te...